For research use only. Not for therapeutic Use.
L6H21 is a specific MD-2 inhibitor and directly binds to MD-2 protein (Kd value of 33.3 μM), blocking the formation of the LPS-TLR4/MD-2 complex.
KEYWORDS: L6H21 | Supplier | MD-2 inhibitor | MD-2 inhibitor L6H21 | CAS [24533-47-9] | [18778-38-6] | DNA-RNA | TLR | Inhibitor | Receptors | Anti-sepsis | Inflammation | Myeloid differentiation 2
| Catalog Number | I047691 |
| CAS Number | 24533-47-9 |
| Molecular Formula | C18H18O4 |
| Purity | ≥95% |
| IUPAC Name | (E)-3-(2,3-dimethoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one |
| InChI | InChI=1S/C18H18O4/c1-20-15-10-7-13(8-11-15)16(19)12-9-14-5-4-6-17(21-2)18(14)22-3/h4-12H,1-3H3/b12-9+ |
| SMILES | COC1=CC=C(C=C1)C(=O)/C=C/C2=C(C(=CC=C2)OC)OC |
| Reference | J Wu et al. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem. 2011 Dec 8;54(23):8110-23. Y Wang et al. MD-2 as the target of a novel small molecule, L6H21, in the attenuation of LPS-induced inflammatory response and sepsis. Br J Pharmacol. 2015 Sep;172(17):4391-405. |
